{"id":"d-fi","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL5875512","moleculeType":null,"molecularWeight":"543.37"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Further research is needed to fully understand the mechanism of action of D-Fi.","oneSentence":"D-Fi is a monoclonal antibody that targets an unspecified mechanism.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:08:20.756Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT04759586","phase":"PHASE3","title":"Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-10-05","conditions":"Primary Mediastinal Large B-Cell Lymphoma","enrollment":244},{"nctId":"NCT03914625","phase":"PHASE3","title":"A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-07-03","conditions":"B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Down Syndrome","enrollment":6720},{"nctId":"NCT05691478","phase":"PHASE2, PHASE3","title":"A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-03-03","conditions":"High Grade Osteosarcoma, Localized Osteosarcoma, Metastatic Osteosarcoma","enrollment":1122},{"nctId":"NCT02180867","phase":"PHASE2, PHASE3","title":"Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-07-11","conditions":"Alveolar Soft Part Sarcoma, Angiomatoid Fibrous Histiocytoma, Atypical Fibroxanthoma","enrollment":140},{"nctId":"NCT00792948","phase":"PHASE2","title":"Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2009-09-01","conditions":"Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1","enrollment":97},{"nctId":"NCT03269669","phase":"PHASE2","title":"Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-01-23","conditions":"Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma","enrollment":73},{"nctId":"NCT04530565","phase":"PHASE3","title":"Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-01-25","conditions":"B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1","enrollment":348},{"nctId":"NCT05675410","phase":"PHASE3","title":"A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-05-11","conditions":"Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8","enrollment":1875},{"nctId":"NCT00379340","phase":"PHASE3","title":"Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2007-04-30","conditions":"Stage III Kidney Wilms Tumor, Stage IV Kidney Wilms Tumor","enrollment":395},{"nctId":"NCT06892639","phase":"PHASE3","title":"Evaluation of D-Fi for the Treatment of Wounds Due to DEB","status":"ACTIVE_NOT_RECRUITING","sponsor":"Castle Creek Biosciences, LLC.","startDate":"2025-03-27","conditions":"Dystrophic Epidermolysis Bullosa","enrollment":32},{"nctId":"NCT03959085","phase":"PHASE3","title":"Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2019-10-31","conditions":"B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Central Nervous System Leukemia","enrollment":5951},{"nctId":"NCT03126916","phase":"PHASE3","title":"Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2018-05-14","conditions":"Ganglioneuroblastoma, Ganglioneuroblastoma, Nodular, Neuroblastoma","enrollment":750},{"nctId":"NCT04199026","phase":"NA","title":"Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2025-02-25","conditions":"Metastatic Sarcoma, Recurrent Sarcoma, Resectable Sarcoma","enrollment":20},{"nctId":"NCT00352534","phase":"PHASE3","title":"Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2006-11-06","conditions":"Stage I Kidney Wilms Tumor, Stage II Kidney Wilms Tumor, Stage III Kidney Wilms Tumor","enrollment":808},{"nctId":"NCT06820957","phase":"PHASE2, PHASE3","title":"Testing a New Combination of Anti-cancer Drugs in Patients Newly Diagnosed With Ewing Sarcoma Who Have Cancer That Has Spread to Other Parts of the Body","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2025-11-10","conditions":"CIC-Rearranged Sarcoma, Metastatic Ewing Sarcoma, Metastatic High Grade Sarcoma","enrollment":437},{"nctId":"NCT03710772","phase":"PHASE2","title":"Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-05-01","conditions":"Mantle Cell Lymphoma","enrollment":51},{"nctId":"NCT04323956","phase":"PHASE1","title":"Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mayo Clinic","startDate":"2020-06-15","conditions":"Ann Arbor Stage II Diffuse Large B-Cell Lymphoma, Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage II Marginal Zone Lymphoma","enrollment":50},{"nctId":"NCT07355816","phase":"NA","title":"Effect of Different Root Canal Disinfection Procedures on Postoperative Pain","status":"COMPLETED","sponsor":"Cumhuriyet University","startDate":"2023-06-13","conditions":"Pain, Postoperative","enrollment":80},{"nctId":"NCT00501826","phase":"PHASE2","title":"Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2007-07-11","conditions":"T Acute Lymphoblastic Leukemia, T Lymphoblastic Lymphoma","enrollment":160},{"nctId":"NCT07072585","phase":"PHASE2, PHASE3","title":"Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)","status":"NOT_YET_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2026-06-28","conditions":"Stage II T Lymphoblastic Leukemia/Lymphoma, Stage III T Lymphoblastic Leukemia/Lymphoma, Stage IV T Lymphoblastic Leukemia/Lymphoma","enrollment":1708},{"nctId":"NCT01424982","phase":"PHASE2","title":"Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2011-10-05","conditions":"Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, Adult Acute Lymphoblastic Leukemia in Complete Remission","enrollment":88},{"nctId":"NCT02112916","phase":"PHASE3","title":"Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-10-04","conditions":"Adult T Acute Lymphoblastic Leukemia, Ann Arbor Stage II Adult Lymphoblastic Lymphoma, Ann Arbor Stage II Childhood Lymphoblastic Lymphoma","enrollment":847},{"nctId":"NCT02883049","phase":"PHASE3","title":"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2012-02-29","conditions":"B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, BCR-ABL1-Like, Central Nervous System Leukemia","enrollment":5949},{"nctId":"NCT02427620","phase":"PHASE2","title":"Ibrutinib, Rituximab, and Consolidation Chemotherapy in Treating Young Patients With Newly Diagnosed Mantle Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-06-03","conditions":"Blastoid Variant Mantle Cell Lymphoma, Mantle Cell Lymphoma, Pleomorphic Variant Mantle Cell Lymphoma","enrollment":131},{"nctId":"NCT02877303","phase":"PHASE2","title":"Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2016-11-01","conditions":"B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma","enrollment":80},{"nctId":"NCT06298734","phase":"NA","title":"High-Intensity Exercise and High-Fiber Diet for Immunotherapy Outcomes in Melanoma Patients: The DUO Trial","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2024-07-01","conditions":"Melanoma (Skin), Skin Cancer, Advanced Melanoma","enrollment":40},{"nctId":"NCT00945009","phase":"PHASE3","title":"Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2009-07-13","conditions":"Adult Kidney Wilms Tumor, Beckwith-Wiedemann Syndrome, Childhood Kidney Wilms Tumor","enrollment":249},{"nctId":"NCT04806386","phase":"NA","title":"The Role of Fiber in the Prevention and Treatment of Fecal Incontinence","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2021-07-21","conditions":"Fecal Incontinence, Irritable Bowel Syndrome With Diarrhea","enrollment":35},{"nctId":"NCT00408005","phase":"PHASE3","title":"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2007-01-30","conditions":"T Acute Lymphoblastic Leukemia, T Lymphoblastic Lymphoma","enrollment":1895},{"nctId":"NCT01190930","phase":"PHASE3","title":"Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2010-08-09","conditions":"Acute Lymphoblastic Leukemia, Adult B Lymphoblastic Lymphoma, Ann Arbor Stage I B Lymphoblastic Lymphoma","enrollment":9350},{"nctId":"NCT03488225","phase":"PHASE2","title":"Combination Chemotherapy and Inotuzumab Ozogamicin in Treating Patients With B Acute Lymphoblastic Leukemia","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-03-28","conditions":"Acute Lymphoblastic Leukemia in Remission, B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative","enrollment":4},{"nctId":"NCT01979536","phase":"PHASE2","title":"Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2013-11-13","conditions":"Anaplastic Large Cell Lymphoma, ALK-Positive, Ann Arbor Stage II Noncutaneous Childhood Anaplastic Large Cell Lymphoma, Ann Arbor Stage III Noncutaneous Childhood Anaplastic Large Cell Lymphoma","enrollment":137},{"nctId":"NCT06374043","phase":"PHASE4","title":"Decentralized N=1 Study: A Feasible Approach to Evaluate Individual Therapy Response to Dapagliflozin.","status":"COMPLETED","sponsor":"University Medical Center Groningen","startDate":"2021-05-11","conditions":"Diabetes Mellitus, Type 2, Diabetes Mellitus Type 2 With Proteinuria, Diabetes Mellitus","enrollment":20},{"nctId":"NCT04626791","phase":"PHASE2","title":"Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma","status":"RECRUITING","sponsor":"Academic and Community Cancer Research United","startDate":"2021-08-03","conditions":"Mantle Cell Lymphoma","enrollment":45},{"nctId":"NCT01527149","phase":"PHASE2","title":"Ofatumumab in Combination With Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine Sulfate, and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"Roswell Park Cancer Institute","startDate":"2011-12-06","conditions":"Stage I Mantle Cell Lymphoma, Stage II Contiguous Mantle Cell Lymphoma, Stage II Non-Contiguous Mantle Cell Lymphoma","enrollment":37},{"nctId":"NCT01606878","phase":"PHASE1","title":"Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2013-04-29","conditions":"Childhood Solid Neoplasm, Recurrent Childhood Anaplastic Large Cell Lymphoma, Recurrent Neuroblastoma","enrollment":46},{"nctId":"NCT03226249","phase":"PHASE2","title":"PET-Directed Therapy With Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Classical Hodgkin Lymphoma","status":"UNKNOWN","sponsor":"Northwestern University","startDate":"2017-11-09","conditions":"Classical Hodgkin Lymphoma, Lymphocyte-Depleted Classical Hodgkin Lymphoma, Lymphocyte-Rich Classical Hodgkin Lymphoma","enrollment":30},{"nctId":"NCT05424796","phase":"PHASE4","title":"Postoperative Pain Intensity After Pulpotomy","status":"COMPLETED","sponsor":"Cumhuriyet University","startDate":"2021-02-15","conditions":"Symptomatic Irreversible Pulpitis","enrollment":90},{"nctId":"NCT02481310","phase":"PHASE1, PHASE2","title":"Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma","status":"UNKNOWN","sponsor":"Northwestern University","startDate":"2015-10-28","conditions":"Adult Burkitt Lymphoma, B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma, Diffuse Large B-Cell Lymphoma","enrollment":38},{"nctId":"NCT00103285","phase":"PHASE3","title":"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2005-04-11","conditions":"Acute Lymphoblastic Leukemia, Childhood B Acute Lymphoblastic Leukemia","enrollment":5377},{"nctId":"NCT01363128","phase":"PHASE2","title":"Combination Chemotherapy and Ofatumumab in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2011-07-12","conditions":"Acute Lymphoblastic Leukemia, Adult Acute Lymphoblastic Leukemia in Complete Remission, Burkitt Leukemia","enrollment":72},{"nctId":"NCT00075725","phase":"PHASE3","title":"Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2003-12-29","conditions":"Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia, Childhood B Acute Lymphoblastic Leukemia","enrollment":3154},{"nctId":"NCT00671034","phase":"PHASE3","title":"Calaspargase Pegol or Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2008-07-21","conditions":"Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia, Childhood B Acute Lymphoblastic Leukemia","enrollment":166},{"nctId":"NCT00866307","phase":"PHASE1","title":"Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia (Closed to Accrual 4-22-2011)","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2009-02-23","conditions":"Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia, Childhood B Acute Lymphoblastic Leukemia","enrollment":104},{"nctId":"NCT04786522","phase":"","title":"Irisin Levels in Patients With Charcot-Marie-Tooth (CMT) Disease","status":"COMPLETED","sponsor":"University of Bari","startDate":"2019-11-02","conditions":"Charcot-Marie-Tooth Disease","enrollment":20},{"nctId":"NCT01697293","phase":"PHASE1, PHASE2","title":"PTX-200, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide in Treating Patients With Stage IIB-IV Breast Cancer","status":"TERMINATED","sponsor":"Prescient Therapeutics, Ltd.","startDate":"2012-01","conditions":"Breast Adenocarcinoma, Estrogen Receptor Positive, HER2/Neu Negative","enrollment":34},{"nctId":"NCT00005970","phase":"PHASE3","title":"Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2000-05-19","conditions":"Breast Adenocarcinoma, HER2 Positive Breast Carcinoma, Stage IA Breast Cancer AJCC v7","enrollment":3436},{"nctId":"NCT02779283","phase":"PHASE1","title":"Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"OHSU Knight Cancer Institute","startDate":"2016-01-13","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia","enrollment":7},{"nctId":"NCT01055314","phase":"PHASE2","title":"Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2010-01","conditions":"Adult Rhabdomyosarcoma, Childhood Alveolar Rhabdomyosarcoma, Childhood Embryonal Rhabdomyosarcoma","enrollment":175},{"nctId":"NCT00025259","phase":"PHASE3","title":"Chemotherapy With or Without Additional Chemotherapy and/or Radiation Therapy in Treating Children With Newly Diagnosed Hodgkin's Disease","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2002-09","conditions":"Childhood Lymphocyte-Depleted Classical Hodgkin Lymphoma, Childhood Mixed Cellularity Classical Hodgkin Lymphoma, Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma","enrollment":1734}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":18,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"D-Fi","genericName":"D-Fi","companyName":"Castle Creek Biosciences, LLC.","companyId":"castle-creek-biosciences-llc","modality":"Biologic","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}